A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions
Alzheimer's Disease
Interventions
DRUG

EHT 0202 etazolate

In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.

DRUG

Placebo

In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.

Trial Locations (22)

12000

Cabinet Médical, Rodez

21000

Cabinet Médical, Dijon

22000

Cabinet Médical, Saint-Brieuc

24100

Cabinet Médical, Bergerac

31059

Purpan-Casselardit Hospital - University of Toulouse, Toulouse

34070

Cabinet Médical, Montpellier

34080

Cabinet Médical 2, Montpellier

35033

CHU Rennes, Rennes

44093

CHU Nantes Hôpital Laennec, Nantes

59037

Roger Salengro Hospital, Lille

75013

CHU Cochin Broca, Paris

78120

Cabinet Médical, Rambouillet

78200

Clinique Léopold Bellan, Magnanville

83000

Cabinet Médical, Toulon

83500

Cabinet Médical, La Seyne-sur-Mer

87042

Dupuytren Hospital, Limoges

91160

Hôpital Privé Les Magnolias, Ballainvilliers

92500

Cabinet Médical, Rueil-Malmaison

94026

Charles Foix Hospital, Ivry-sur-Seine

01012

Fleyriat Hospital, Bourg-en-Bresse

06000

Cabinet Médical 2, Nice

Cabinet Médical, Nice

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Exonhit

INDUSTRY